155 related articles for article (PubMed ID: 36941224)
21. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract][Full Text] [Related]
23. Sinomenine inhibits hypoxia induced breast cancer side population cells metastasis by PI3K/Akt/mTOR pathway.
Song L; Zhang H; Hu M; Liu C; Zhao Y; Zhang S; Liu D
Bioorg Med Chem; 2021 Feb; 31():115986. PubMed ID: 33412412
[TBL] [Abstract][Full Text] [Related]
24. The Anticancer Effects of Marine Carotenoid Fucoxanthin through Phosphatidylinositol 3-Kinase (PI3K)-AKT Signaling on Triple-Negative Breast Cancer Cells.
Ahmed SA; Mendonca P; Messeha SS; Oriaku ET; Soliman KFA
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202644
[TBL] [Abstract][Full Text] [Related]
25. Study of the PI3K/Akt/mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.
Liu X; Liu J; Yan B; Quan Z; Wang X; Ma Y; Alarfaj AA; Yan L
Environ Toxicol; 2024 Jan; 39(1):444-456. PubMed ID: 37792628
[TBL] [Abstract][Full Text] [Related]
26. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
Cheng W; Liu D; Guo M; Li H; Wang Q
Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
28. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
29. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways.
Qu Z; Lin Y; Mok DK; Bian Q; Tai WC; Chen S
Int J Med Sci; 2020; 17(11):1482-1490. PubMed ID: 32669950
[TBL] [Abstract][Full Text] [Related]
30. Involvement of AKT/PI3K Pathway in Sanguinarine's Induced Apoptosis and Cell Cycle Arrest in Triple-negative Breast Cancer Cells.
Messeha SS; Noel S; Zarmouh NO; Womble T; Latinwo LM; Soliman KFA
Cancer Genomics Proteomics; 2023; 20(4):323-342. PubMed ID: 37400144
[TBL] [Abstract][Full Text] [Related]
31. Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.
Tohkayomatee R; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
Molecules; 2022 May; 27(11):. PubMed ID: 35684480
[TBL] [Abstract][Full Text] [Related]
32. Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway.
Jia W; Lin X; Chen X; Li H; Zhang X; Zhang Y; Chen Y; Wang B; Chen X; Chen J; Tian H
J Ethnopharmacol; 2024 Jun; 327():118011. PubMed ID: 38467320
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
34. Disruption of the PI3K/AKT/mTOR signaling cascade and induction of apoptosis in HL-60 cells by an essential oil from Monarda citriodora.
Pathania AS; Guru SK; Verma MK; Sharma C; Abdullah ST; Malik F; Chandra S; Katoch M; Bhushan S
Food Chem Toxicol; 2013 Dec; 62():246-54. PubMed ID: 23994707
[TBL] [Abstract][Full Text] [Related]
35. DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
Colín-Val Z; López-Díazguerrero NE; López-Marure R
J Steroid Biochem Mol Biol; 2021 Apr; 208():105818. PubMed ID: 33508440
[TBL] [Abstract][Full Text] [Related]
36. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells.
Zhang Y; Zhao Z; Li S; Dong L; Li Y; Mao Y; Liang Y; Tao Y; Ma J
Mol Med Rep; 2019 May; 19(5):4035-4042. PubMed ID: 30942417
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
[TBL] [Abstract][Full Text] [Related]
39. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
[TBL] [Abstract][Full Text] [Related]
40. MAT as a promising therapeutic strategy against triple-negative breast cancer via inhibiting PI3K/AKT pathway.
Wei S; Zhang Y; Ma X; Yao Y; Zhou Q; Zhang W; Zhou C; Zhuang J
Sci Rep; 2023 Jul; 13(1):12351. PubMed ID: 37524857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
